Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

THURSDAY, Nov. 29, 2018 -- Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news